Karyopharm Therapeutics (KPTI) Gross Profit (2019 - 2025)

Karyopharm Therapeutics has reported Gross Profit for 6 years, with the latest figure at $32.7 million in Q4 2025.

• For the quarter ending Q4 2025, Gross Profit rose 12.07% year-over-year to $32.7 million; the trailing twelve-month figure through Dec 2025 stood at $140.4 million (up 0.78% YoY), and the FY2025 full-year result was $140.3 million, up 0.74% from the prior year.
• Gross Profit for Q4 2025 stood at $32.7 million, down from $42.0 million in the prior quarter.
• The five-year high for Gross Profit was $125.5 million in Q4 2021, with the low at $21.5 million in Q2 2021.
• Historically, Gross Profit has averaged $39.8 million across 5 years, with a median of $36.4 million in 2023.
• The largest YoY upside for Gross Profit was 80.5% in 2022 against a maximum downside of 74.74% in 2022.
• Karyopharm Therapeutics' Gross Profit stood at $125.5 million in 2021, then plunged by 74.74% to $31.7 million in 2022, then rose by 1.73% to $32.3 million in 2023, then slipped by 9.45% to $29.2 million in 2024, then increased by 12.07% to $32.7 million in 2025.
• The last three Gross Profit figures came in at $32.7 million (Q4 2025), $42.0 million (Q3 2025), and $36.9 million (Q2 2025), per Business Quant data.